Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature

Sara Massironi1*, Alessandra Zilli1, Roberta Elisa Rossi1,2, Federica Cavalcoti1,2, Dario Conte1,2 and Maddalena Peracchi2

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors have occasionally been described in association with neurofibromatosis type 1, whereas an association with neurofibromatosis type 2 has never been reported.

Case presentation: This report refers to an Italian 69 year old woman with neurofibromatosis type 2 and a pancreatic gastrinoma. In the past she had encephalic meningiomas, a tongue schwannoma and bilateral acoustic neurinomas. She presented with weight loss and a long-term history of diarrhea, responsive to proton pump inhibitors. Upper gastrointestinal endoscopy revealed peptic ulcer of the duodenal bulb. Blood tests were normal, except for the elevation of plasma gastrin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value <36). After secretin stimulation testing, the plasma gastrin level rose to 3789 pg/ml. The abdomen magnetic resonance imaging and gallium68-DOTATOC positron emission tomography scan demonstrated the presence of a 1.2 x 2 cm lesion in the pancreatic head and a liver metastasis. Pancreatic endoscopic ultrasound with fine needle aspiration revealed cytomorphologic features suggestive of pancreatic gastrinoma. Brain magnetic resonance showed a pituitary microadenoma. There was no evidence of hyperparathyroidism. The genetic test for multiple endocrine neoplasia type 1 syndrome mutation was negative.

Conclusion: This report focuses on the first case of coexistence of gastrinoma with neurofibromatosis type 2. Although the clinical relevance of this association remains to be determined, our case report will surely give cause for due consideration.

Keywords: Gastrinoma, Neurofibromatosis type 2, Multiple endocrine neoplasia syndrome type 1, Neuroendocrine tumors, Zollinger Ellison syndrome

Background

Both gastroenteropancreatic neuroendocrine tumors (GEP NET) and neurofibromatosis type 2 (NF2) are fairly rare diseases [1,2]. GEP NET have occasionally been described in association with neurofibromatosis type 1 (NF1) [3], whereas an association with NF2 has never been reported.

Gastrinoma is a gastrin-secreting tumor usually located in the duodenal wall or in the pancreas [4]. Chronic hypergastrinemia causes gastric acid hypersecretion with consequent peptic ulcer disease, diarrhea and gastroesophageal reflux disease (Zollinger Ellison syndrome, ZES), usually responsive to proton pump inhibitor (PPI) therapy. With an incidence of 0.5-2/million population/year gastrinoma may be sporadic or may develop in the setting of multiple endocrine neoplasia type 1 (MEN1) syndrome [5-8]. The tumors associated with MEN1 syndrome have a more benign course than sporadic neuroendocrine tumors, although more aggressive tumors have rarely been described in association with MEN1 syndrome [9]. MEN1 is an autosomal dominant inherited disease, due to inactivating mutations of the MEN1 gene, located on the long arm of chromosome 11 (11q13) [10]. Diagnostic criteria for MEN1 include the presence of at least two of the three main MEN1 associated lesions (primary hyperparathyroidism, GEP NET and anterior pituitary tumors) or the association of any typical MEN1-associated neoplasia and a positive familial history [11]. Diagnostic confirmation is achievable through MEN1 genetic testing.

According to available data, an association between GEP NET and NF1 has already been reported and it is well recognized that NF1 patients may develop NET,
usually in the duodenum or periampullary region [12-14] and occasionally in the pancreas [15]. Gastric carcinoids have also been described [16].

NF2 is an autosomal dominant inherited disease characterized by the predisposition to develop tumors of the central nervous system (CNS) [2]. NF2 is caused by mutations of the NF2 gene that codes for an oncosuppressor protein named merlin or schwannomin and is located on chromosome 22 (22q12.2) [17]. A common manifestation of the disease is the development of vestibular schwannomas, tumors in other cranial nerves and meningiomas, usually multifocal and intracranial, but sometimes also spinal or intradural [18].

At present an association between GEP NET and NF2 has never been reported. The present case report refers to a woman with NF2 and a pancreatic gastrinoma.

**Case presentation**

In 2011 an Italian 69 years old woman was referred to our Gastrointestinal Unit due to an 8 years long history of diarrhea, dyspepsia and weight loss. Diarrhea was responsive to PPI. Two years before (2009) she was diagnosed as having NF2 syndrome, according to internationally accepted clinical criteria [19], based on the finding of multiple encephalic meningiomas (partially removed by surgery), a tongue schwannoma and bilateral acoustic neurinomas. In addition, a non-functioning adrenal adenoma, has also been diagnosed. To investigate the cause of diarrhea, the patient had already undergone both a colonoscopy, negative, and an upper gastrointestinal endoscopy, which provided clear cut evidence of a duodenal bulb ulceration; during the endoscopy the measurement of intra-gastric pH was not performed, since the patient was on PPI. After two weeks of PPI withdrawal laboratory tests revealed a marked increase in plasma gastrin levels (1051 pg/ml; reference value, r.v. <108), chromogranin A (337 U/L; r.v. <36), glucagon (524 pg/ml; r.v. 25–250).

The liver, kidney, thyroid and parathyroid function tests were normal. Moreover, secondary causes of hypergastrinemia were excluded.

A secretin stimulation test (Secrelux 2U/Kg, Goldham-Bioglan, Zusmarhausen, Germany) was performed and showed a diagnostic increase in plasma gastrin levels (1051 pg/ml; reference value, r.v. <108), chromogranin A (337 U/L; r.v. <36), glucagon (524 pg/ml; r.v. 25–250). The liver, kidney, thyroid and parathyroid function tests were normal. Moreover, secondary causes of hypergastrinemia were excluded.

A secretin stimulation test (Secrelux 2U/Kg, Goldham-Bioglan, Zusmarhausen, Germany) was performed and showed a diagnostic increase in plasma gastrin levels (1051 pg/ml; reference value, r.v. <108), chromogranin A (337 U/L; r.v. <36), glucagon (524 pg/ml; r.v. 25–250). The increase from 1031 to 3789 pg/ml was observed within ten minutes.

A secretin stimulation test (Secrelux 2U/Kg, Goldham-Bioglan, Zusmarhausen, Germany) was performed and showed a diagnostic increase in plasma gastrin levels (1051 pg/ml; reference value, r.v. <108), chromogranin A (337 U/L; r.v. <36), glucagon (524 pg/ml; r.v. 25–250). The increase from 1031 to 3789 pg/ml was observed within ten minutes.

**Conclusions**

We have reported the first case report of the association between NF2 and a pancreatic gastrinoma, although it remains to be determined whether this association is merely casual or not. The possible underlying pathogenetic mechanisms need also elucidation.

The association between NF1 and GEP NET has already been established. Several case reports and reviews of the literature describe the coexistence of NF1 and neuroendocrine neoplasms, such as somatostatinomas, gastrinomas [20], insulinomas [21] and gastric carcinoids [8-12]. In patients with NF1 NETs are most commonly localized in the duodenum and in the peri-ampullary region. Although
NF1 associated duodenal neuroendocrine tumors are not distinctive, they tend to be pure somatostatinomas [22,23] or less frequently gastrinomas, whereas duodenal tumors not associated with NF1 are frequently multihormonal, but asymptomatic [24]. Other gastrointestinal manifestations can occur in several locations, in the form of gastrointestinal stromal tumors or ganglioneuromas [3]. Also an association between NF1 and MEN2A is described in one case report [25].

As concerns patients with NF2, schwannomas of the intestinal tract are a possible complication [26], whereas there are no data about coexistence with GEP NET and/or MEN1 syndrome.

An increased occurrence of endocrine tumors, as well as of other non endocrine tumors, including collagenomas, ependimomas, schwannomas and meningiomas has been recently reported in patients with MEN1 [27-29]. Meningiomas arising in MEN1 setting are usually silent, thus the diagnosis is often late, with a mean interval of 18 years from the diagnosis of MEN1; they have a higher incidence in patients with ZES in the MEN1 setting than in patients with sporadic ZES [30].

The present report focuses on the first case of gastrinoma in a NF2 patient. This patient might have a MEN1 like phenotype, as she showed the clinical features typical of MEN1 syndrome (pancreatic neuroendocrine tumor, pituitary microadenoma and adrenal adenoma), despite the absence of hyperparathyroidism and MEN1 gene mutations. The phenotype of MEN1 is broad and different combinations of endocrine and non endocrine manifestations have been described. About 30% MEN1 patients do not carry detectable MEN1 gene mutations [31]. Patients without detectable mutations may have mutations in introns or in the regulatory or untranslated regions. Moreover, the polymerase chain reaction does not reveal a large deletion causing the loss of a whole exon. Recently, germ line mutations have been found in the CDKN1B gene, encoding a cyclin dependent kinase inhibitor protein that inhibits cell cycle progression [32,33], even if only 1.6-2.8% of all tested cases of MEN1 have CDKN1B mutations [34]. The possible pathogenic mechanisms underlying the dual development of gastrinoma and NF2 remain to be elucidated. Interestingly, a possible explanation for the high prevalence of neuroendocrine tumors in NF1 might be the loss of neurofibromin, a tumor suppressor protein, representing the main product of the NF1 gene. Again, the mutation of the G protein Ras, often seen in NF1 tumors, could promote tumorigenesis due to a prolonged or persistent arrest in the activated GTP loaded state. Recent studies have clearly shown that also the tumor-suppressor protein merlin,
mutated in NF2, controls Ras activity [35]. Furthermore, Merlin probably regulates angiogenesis to support schwannoma growth, although the exact mechanisms are still unexplored [36]. Angiogenesis is an important determinant of tumor growth also in neuroendocrine neoplasms, so Merlin could influence their development and growth. Another possible explanation of the association between NF2 and GEP NET may be the likely common embryological origin of nervous and neuroendocrine cells from the neural crest, although some authors have recently suggested that the neuroendocrine system might originate from the endoderm [37,38].

Overall, the possible pathogenic mechanisms underlying the occurrence of both gastrinoma and NF2, which would allow to discriminate between an actual connection and a merely casual association, remain to be elucidated.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for the Editor-in-Chief of this journal.

Abbreviations
GEP NET: Gastroenteropancreatic neuroendocrine tumors; NF2: Neurofibromatosis type 2; NF1: Neurofibromatosis type 1; ZES: Zollinger-Ellison syndrome; PPI: Proton pump inhibitor; MEN1: Multiple endocrine neoplasia type 1; CNS: Central nervous system; MR: Magnetic resonance; PET: Positron emission tomography.

Competing interests
We have no conflict of interest to declare.

Authors' contributions
SM planned the work. SM, AZ and REJR wrote the paper and subsequently performed its critical review, contributing equally to this work. AZ and FC carried out the literature research; MP contributed to the acquisition of data and their interpretation. DC and MP revised all the materials and manuscript. All authors read and approved the final manuscript.

Acknowledgments
The authors acknowledge Paolo Giorgio Arcidiacono, MD and Silvia Carrara, MD (Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy) for their help in patient clinical management, and Marcello Hinxman-Allegri for the linguistic revision.

Author details
1Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Università degli Studi di Milano, Via F. Sforza 35, Milano 20122, Italy. 2Department of Pathophysiology and Organ Transplant, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Received: 13 August 2013 Accepted: 13 June 2014 Published: 24 June 2014

References
1. Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol 2010, 21:72–80.
2. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009, 4:16. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Evans+DG%3A+Neurofibromatosis+type+2%3A+clinical+and+molecular+review&redirectedFrom=Orphanet%2Fj+Rare+Dis%3A2009%2C+4%3A+16).
3. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 1991, 19:1–11.
4. Krampitz JW, Norton JA. Current management of the Zollinger-Ellison syndrome. Adv Surg 2013, 47:59–79.
5. Ro T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013, 29:550–561.
6. Jensen RT, Niederle B, Mityt E, Ramag JN, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Koppel G, Frascati. Consensus Conference: European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006, 84:173–182.
7. Klöppel G, Anlauf M. Gastrinoma—morphological aspects. Wien Klin Wochenschr 2007, 119:579–584.
8. Anlauf M, Garbrecht N, Henopp T, Schmidt A, Schlegler R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Draife H, Komminoth P, Heitz PU, Perren A, Klöppel G. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinic-pathological and epidemiological features. World J Gastroenterol 2006, 12:5440–5446.
9. Akerström G, Hesman O, Hellman P, Skogseid B. Pancreatic NETs: Gastroenteropancreatic neuroendocrine tumors; a clinical and molecular review. Orphanet J Rare Dis 2009, 4:16.
10. Piecha G, Chudek J, Wiecek A. Multiple Endocrine Neoplasia type 1 revisited. Pediatrics 2009, 23:124–133.
11. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009, 2014, 119:993–106.
12. Ford KP, Korf BR, Theo A. Neurofibromatosis type 1. J Am Acad Dermatol 2009, 61:1–16.
13. Nishi T, Kabata H, Yari H, Imaoka H, Ishikawa N, Yano S, Maruyama R, Tajima Y. A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis type 1. World J Surg Oncol 2012, 10:153.
14. Stewart W, Traynor JP, Cooke A, Griffiths S, O’Connor JM, Pauwels S, Kloppel G, scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012, 97:3990–3911.
15. Reche G, Crudek J, Weeck A. Multiple Endocrine Neoplasia type 1. Eur J Endocrinol Med 2008, 199:99–103.
16. Ferrer RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet 2007, 44:881–88.
17. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009, 23:124–133.
18. Boyd KP, Korf BR, Theo A. Neurofibromatosis type 1. J Am Acad Dermatol 2009, 61:1–16.
19. Nishi T, Kabata H, Yari H, Imaoka H, Ishikawa N, Yano S, Maruyama R, Tajima Y. A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis type 1. World J Surg Oncol 2012, 10:153.
20. Stewart W, Traynor JP, Cooke A, Griffiths S, O’Connor JM, Pauwels S, Kloppel G, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012, 97:3990–3911.
21. Reche G, Crudek J, Weeck A. Multiple Endocrine Neoplasia type 1. Eur J Endocrinol Med 2008, 199:99–103.
22. Ferrer RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet 2007, 44:881–88.
23. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009, 23:124–133.
24. Boyd KP, Korf BR, Theo A. Neurofibromatosis type 1. J Am Acad Dermatol 2009, 61:1–16.
25. Nishi T, Kabata H, Yari H, Imaoka H, Ishikawa N, Yano S, Maruyama R, Tajima Y. A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis type 1. World J Surg Oncol 2012, 10:153.
26. Stewart W, Traynor JP, Cooke A, Griffiths S, O’Connor JM, Pauwels S, Kloppel G, Scarpa A, Sundin A, Perren A, Gross D, O’Connor JM, Pauwels S, Kloppel G, Frascati. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012, 97:3990–3911.
27. Kato H, Uchimura I, Morohoshi M, Fujisawa K, Kobayashi Y, Numano F, Goseki N, Endo M, Tamura A, Nagashima C. Multiple endocrine neoplasia type 1 associated with spinal ependymoma. *Intern Med* 1996, 35:285–289.

28. Chigot JP, Bendib S, Turpin G, Benlian P. Characteristic pathological associations in multiple endocrine neoplasia type 1. *Presse Med* 1996, 25:1229–1233.

29. Banik S, Hasketon PS, Lyon R.L. An unusual variant of multiple endocrine neoplasia syndrome: a case report. *Histopathology* 1984, 8:135–144.

30. Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer A, Zhuang Z, Venzon DJ, Gibril F, Jensen RT. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. *Clin Cancer Res* 2004, 10:869–880.

31. Ozawa A, Agarwal SK, Mateo CM, Burns AL, Rice TS, Kennedy PA, Quigley CM, Simonds WF, Weinstein LS, Chandrasekharamappa SC, Collins FS, Spiegel AM, Marx SJ. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. *J Clin Endocrinol Metab* 2007, 92:1948–1951.

32. Pellegata NS, Quintanilla-Martinez L, Sigelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. *Proc Natl Acad Sci U S A* 2006, 103:15558–15563.

33. Agarwal SK, Mateo CM, Marx SJ. Rare germ line mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. *J Clin Endocrinol Metab* 2009, 94:1826–1834.

34. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Tuppurainen K, Paschke R, Gimmi O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izzet I, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. *J Clin Endocrinol Metab* 2007, 92:3321–3325.

35. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. *Cancer Res* 2007, 67:520–527.

36. Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, Klagsbrun M, Jain RK. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3 F-dependent mechanism. *Neoplasia* 2012, 14:94–94.

37. Rawdon BB, Andrew A. Origin and differentiation of gut endocrine cells. *Histol Histopathol* 1993, 8:567–580.

38. Sidhu GS. The endodermal origin of digestive and respiratory tract APUD cells. *Histopathologic evidence and a review of the literature. Am J Pathol* 1979, 96:5–20.

doi:10.1186/1471-230X-14-110
Cite this article as: Massironi et al. Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. *BMC Gastroenterology* 2014 14:110.